Trial Filter
BETAAn intelligent search tool for clinical trials
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Eligibility Criteria
Inclusion Criteria
- 1Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent.
- 2Documented estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumor
- 3Documented HER2-negative tumor
- 4Previously untreated with any systemic anticancer therapy for their locally advanced or metastatic disease.
- 5Measurable disease or non-measurable bone only disease as defined by RECIST version 1.1
Exclusion Criteria
- 1In visceral crisis at risk of immediately life-threatening complications in the short term.
- 2Current or past history of central nervous system metastases.
- 3Have received prior (neo)adjuvant endocrine therapy (ET) and had recurrence during or within 12 months after the last dose of ET.
- 4Have received prior (neo)adjuvant CDK4/6i and had recurrence during or within 12 months after the last dose of CDK4/6i.
- 5Inadequate renal function, hepatic dysfunction, or hematologic abnormalities.
Locations
452 sites participating in this study
Emory University Hospital Midtown
Atlanta, Georgia 30308
Emory University Hospital
Atlanta, Georgia 30322
Winship Cancer Institute
Atlanta, Georgia 30322